Form 4: Moderna CLO Converts RSUs, Sells Shares for Tax

Moderna's Chief Legal Officer, Shannon Thyme Klinger, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

Summary

• Shannon Thyme Klinger, Moderna's Chief Legal Officer, converted 11,797 Restricted Stock Units (RSUs) into common stock on March 5, 2026.
• Concurrently, 5,704 shares of common stock were disposed of at a price of $57.8 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Klinger beneficially owns 65,782 shares of common stock directly.
• Klinger also holds 129,774 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and tax management, which is a standard part of executive equity programs.

Positives

• The vesting of 11,797 restricted stock units demonstrates continued compensation and retention of a key executive within Moderna.

Negatives

• The disposition of 5,704 shares, although for tax purposes, reduces the direct common stock holdings of the Chief Legal Officer.

Future Outlook

The remaining 75% of the restricted stock unit award will vest in twelve equal quarterly installments following the initial vesting on December 5, 2025.

Industry Context

StockSavvy.ai notes that executive compensation often includes equity awards like Restricted Stock Units (RSUs), which vest over time to align executive interests with shareholder value. The conversion and subsequent sale for tax purposes are standard practices in managing such compensation across the industry.

Stakeholder Impact

• Shareholders: Minor dilution from RSU conversion, but also signals executive retention and alignment of interests.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• The remaining 75% of the restricted stock unit award will vest in twelve equal quarterly installments.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are common and do not typically indicate a change in the company's fundamental outlook or the executive's confidence beyond standard compensation management. Therefore, a "hold" recommendation is appropriate as this filing does not provide new information warranting a change in investment thesis.

Keywords

Moderna, MRNA, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, RSU, Stock Sale, Tax Withholding